Research Assays

Fully automated detection of 46 EGFR mutations, directly from 1 FFPE tissue section.

Fully automated detection of ALK, ROS1, RET, NTRK1/2/3 rearrangements & MET exon 14 skipping, directly from 1 FFPE tissue section.

Fully automated detection of 7 BRAF mutations, directly from 1 FFPE tissue section.

Fully automated, first-in-class cartridge-based assay for risk stratification of indeterminate thyroid nodules.

Fully automated detection of 21 KRAS mutations, directly from 1 FFPE tissue section.

Fully automated detection of 18 NRAS, 5 BRAF and 2 EGFR mutations, directly from 1 FFPE tissue section.

Fully automated detection of 7 monomorphic biomarkers, directly from 1 FFPE tissue section.

Fully automated detection of 17 POLE mutations and 1 POLD1 mutation, directly from 1 FFPE tissue section.

Fully automated detection of 5 IDH mutations and 10 IDH2 mutations, directly from FFPE tissue sections, whole blood, BMA or extracted DNA.

*TEMPORARILY UNAVAILABLE

Fully automated detection of 13 PIK3CA mutations and 1 AKT1 mutation, directly from 1 FFPE tissue section.

Fully automated detection of 49 EGFR mutations, directly from 2 ml of plasma.

Fully automated detection of 21 KRAS mutations, directly from 1 ml of plasma

Fully automated detection of 18 NRAS, 5 BRAF and 2 EGFR mutations, directly from 1 ml of plasma.

Qualitative detection of 11 ESR1 mutations via quantitative PCR (qPCR), using DNA extracted from FFPE tissue section or plasma.

Qualitiative detection of 11 ESR1 mutations via digital PCR (dPCR), using DNA extracted from FFPE tissue section or plasma.

Qualitative detection of 5 PIK3CA mutations via quantitative PCR (qPCR), using DNA extracted from FFPE tissue section or plasma.

Gene expression quantification of standard biomarkers (HER2, ER, PR, Ki67) and a novel proliferative signature from pre-operative core needle biopsies (CNB) or FFPE resected breast tumor tissue.